244 related articles for article (PubMed ID: 21742432)
1. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
[TBL] [Abstract][Full Text] [Related]
2. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
4. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
5. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
[No Abstract] [Full Text] [Related]
7. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma.
Yang M; Fan WF; Pu XL; Liu FY; Meng LJ; Wang J
Oncol Lett; 2014 Jan; 7(1):227-232. PubMed ID: 24348854
[TBL] [Abstract][Full Text] [Related]
8. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.
Jung M; Lee CH; Park HS; Lee JH; Kang YA; Kim SK; Chang J; Kim DJ; Rha SY; Kim JH; Cho BC
Yonsei Med J; 2013 Jul; 54(4):854-64. PubMed ID: 23709418
[TBL] [Abstract][Full Text] [Related]
10. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
11. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed‑resistant lung adenocarcinoma A549 cell line.
Yu Z; Li XM; Liu SH; Liu B; Gao CH; Hou X
Oncol Rep; 2014 Apr; 31(4):1818-24. PubMed ID: 24549863
[TBL] [Abstract][Full Text] [Related]
13. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and mechanism of action of pemetrexed.
Adjei AA
Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S51-5. PubMed ID: 15117425
[TBL] [Abstract][Full Text] [Related]
15. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
16. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
17. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
19. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
20. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.
Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hoffmann S; Hanauske-Abel H; Ma D; Chen V; Paoletti P; Niyikiza C
Invest New Drugs; 2007 Oct; 25(5):417-23. PubMed ID: 17534577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]